Medtronic Receives CE Mark for Penditure LAA Clip, Set for European Launch

Medtronic has secured a CE mark for its Penditure left atrial appendage (LAA) exclusion system and plans to launch the device in Europe next week, positioning it as a competitor to AtriCure’s AtriClip. Penditure, acquired through Medtronic’s takeover of Syntheon, was introduced in the U.S. in 2023 and has already sold over 10,000 units globally. The clip is used during cardiac surgeries to close the LAA, a key source of stroke-causing clots in patients with atrial fibrillation, distinguishing it from minimally invasive devices such as Abbott’s Amplatzer Amulet and Boston Scientific’s Watchman.

Medtronic highlighted Penditure’s unique feature: it can be recaptured, repositioned, and redeployed during surgery. The company plans to showcase the European launch at the European Association for Cardio-Thoracic Surgery Annual Meeting in Copenhagen. The device is expected to drive low-double-digit growth in Medtronic’s cardiac surgery segment, while challenging AtriCure, whose LAA products saw 26% international sales growth in the first half of 2025.

07-10-2025